Nanoform

Nanoform (Helsinki, Finland) is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce attrition in clinical trials and enhance their molecules’ formulation performance through its nanoforming™ services. The Company’s patented and scalable Controlled Expansion of Supercritical Solutions (CESS®) technology produces nano-formed active pharmaceutical ingredient particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability. Nanoform’s unique technology provides novel opportunities in many value-enhancing, drug delivery applications.

 

Website: https://nanoform.com/en/

Email: [email protected]

Telephone: +358 29 370 0150

Address: Cultivator II, Viikinkaari 4, FI-00790 Helsinki, Finland

Watch Christian Jones, Chief Commercial Officer at Nanoform (Helsinki, Finland), discuss some of the challenges that exist in the current drug discovery and development market, how nanoparticles and nanotechnology may impact drug delivery, pharmaceutical efficiency and drug doses, and what Nanoform’s mission in all this is.

First-in-human trial of CESS®-nanoformed drug on track to begin by end of 2020

Nanoform announces biological nanoparticle-forming technology

Nanoform makes US TV debut in Advancements with Ted Danson (CNBC)

Nanoform and Herantis partner to look for opportunities to enhance BBB penetration of CDNF and xCDNF molecules

First dosing of nanoformed drug successfully accomplished

Nanoform’s clinical study indicates positive interim results

Nanoform and Herantis sign Biologics Proof of Concept Agreement

Additional positive interim results from Nanoform’s clinical study

Nanoform’s final clinical results confirm value proposition to the pharma industry

Nanoform and Celanese explore ways to enhance drug delivery